The FDA and DEA Disagree Over CBD Scheduling

Canna Law Blog
By Nathalie BougeniesOct 11, 2018, 10:00 am190 pts
FDA and DEA are in a bit of a tiff over CBD. Last week, following the highly-anticipated U.S. Food and Drug Administration (“FDA”) approval of Epidiolex, G.W. Pharma’s oral cannabidiol (“CBD”) solution for the treatment of seizure associated with Lennox-Gastraut and Dravet syndrome, the Drug Enforcement…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

AYR Wellness Announces Commencement of Restructuring Support Agreement Article 9 Proceedings 78

Psychedelics Show Promise As An ‘Entirely New Type Of Anti-Inflammatory Treatment,’ Research Suggests 77

California Governor Signs Bill To Expedite Marijuana And Psychedelics Research 74

Portland Dispensary Employee Found Not Guilty After Deadly Robbery Encounter 71

Hemp Companies Sue Ohio Governor Over Hemp THC Ban 70

Planet 13 Opens Florida Dispensary in DeLand 61

MSO Curaleaf Lawsuit Filed Against NJ-CRC Over State Labor Law 61

Michigan Cannabis Sales Sank in September 50

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.